-
Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise
Thursday, December 9, 2021 - 2:18pm | 293Read More...Frequency Therapeutics Inc (NASDAQ: FREQ) shared the results from its FX-322-113 study of FX-322 in severe sensorineural hearing loss (SNHL). The Phase 1b study, FX-322, was associated with a hearing signal, as shown by improvements by four subjects in a sentence-in-noise test. In...
-
Regeneron Extends Hearing Loss Gene Therapy pact With Decibel
Monday, November 22, 2021 - 11:33am | 269Read More...Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has extended the research term of its collaboration with Decibel Therapeutics Inc (NASDAQ: DBTX) to discover and develop gene therapies for hearing loss. The research term is extended to November 15, 2023, and Regeneron...
-
Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors
Wednesday, September 22, 2021 - 11:18am | 306Read More...Frequency Therapeutics Inc (NASDAQ: FREQ) has announced that four additional sensorineural hearing loss (SNHL) subjects from its FX-322-111 open-label study achieved statistically significant hearing improvements. The patients were evaluated 8 to 12 months following initial dosing....
-
Frequency Therapeutics Stock Craters After FX-322's Four Weekly Regime Shows No Benefit In Sensorineural Hearing Loss
Tuesday, March 23, 2021 - 7:54am | 441Read More...Frequency Therapeutics Inc (NASDAQ: FREQ) stock plunges in the premarket after reporting topline day-90 data from its Phase 2a study (FX-322-202) evaluating the company's lead product candidate FX-322 in sensorineural hearing loss (SNHL). What Happened: Final results...
-
Decibel Therapeutics' Hearing Loss Gene Therapy Shows Potential In Preclinical Studies
Wednesday, February 24, 2021 - 2:52pm | 256Read More...Decibel Therapeutics Inc (NASDAQ: DBTX) presented preclinical data of its gene therapy candidate, DB-OTO, for hearing loss due to mutation of the otoferlin gene. Decibel presented the data at the Annual MidWinter Meeting of the Association for Research in Otolaryngology. DB-OTO...
